Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Price, Quote, News and Overview

NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD

63.51  +0.73 (+1.16%)

After market: 64.1061 +0.6 (+0.94%)

SRPT Quote, Performance and Key Statistics

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (5/2/2025, 8:24:12 PM)

After market: 64.1061 +0.6 (+0.94%)

63.51

+0.73 (+1.16%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High173.25
52 Week Low48.01
Market Cap6.24B
Shares98.26M
Float92.95M
Yearly DividendN/A
Dividend YieldN/A
PE27.86
Fwd PE8.85
Earnings (Next)05-06 2025-05-06/amc
IPO06-04 1997-06-04


SRPT short term performance overview.The bars show the price performance of SRPT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

SRPT long term performance overview.The bars show the price performance of SRPT in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of SRPT is 63.51 USD. In the past month the price increased by 8.36%. In the past year, price decreased by -52.48%.

SAREPTA THERAPEUTICS INC / SRPT Daily stock chart

SRPT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About SRPT

Company Profile

SRPT logo image Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,372 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Company Info

SAREPTA THERAPEUTICS INC

215 1st St Ste 415

Cambridge MASSACHUSETTS 02142 US

CEO: Douglas S. Ingram

Employees: 1372

SRPT Company Website

SRPT Investor Relations

Phone: 16172744000

SAREPTA THERAPEUTICS INC / SRPT FAQ

What is the stock price of SAREPTA THERAPEUTICS INC today?

The current stock price of SRPT is 63.51 USD. The price increased by 1.16% in the last trading session.


What is the ticker symbol for SAREPTA THERAPEUTICS INC stock?

The exchange symbol of SAREPTA THERAPEUTICS INC is SRPT and it is listed on the Nasdaq exchange.


On which exchange is SRPT stock listed?

SRPT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SAREPTA THERAPEUTICS INC stock?

31 analysts have analysed SRPT and the average price target is 154.99 USD. This implies a price increase of 144.05% is expected in the next year compared to the current price of 63.51. Check the SAREPTA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SAREPTA THERAPEUTICS INC worth?

SAREPTA THERAPEUTICS INC (SRPT) has a market capitalization of 6.24B USD. This makes SRPT a Mid Cap stock.


How many employees does SAREPTA THERAPEUTICS INC have?

SAREPTA THERAPEUTICS INC (SRPT) currently has 1372 employees.


What are the support and resistance levels for SAREPTA THERAPEUTICS INC (SRPT) stock?

SAREPTA THERAPEUTICS INC (SRPT) has a resistance level at 63.52. Check the full technical report for a detailed analysis of SRPT support and resistance levels.


Is SAREPTA THERAPEUTICS INC (SRPT) expected to grow?

The Revenue of SAREPTA THERAPEUTICS INC (SRPT) is expected to grow by 63.91% in the next year. Check the estimates tab for more information on the SRPT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SAREPTA THERAPEUTICS INC (SRPT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SAREPTA THERAPEUTICS INC (SRPT) stock pay dividends?

SRPT does not pay a dividend.


When does SAREPTA THERAPEUTICS INC (SRPT) report earnings?

SAREPTA THERAPEUTICS INC (SRPT) will report earnings on 2025-05-06, after the market close.


What is the Price/Earnings (PE) ratio of SAREPTA THERAPEUTICS INC (SRPT)?

The PE ratio for SAREPTA THERAPEUTICS INC (SRPT) is 27.86. This is based on the reported non-GAAP earnings per share of 2.28 and the current share price of 63.51 USD. Check the full fundamental report for a full analysis of the valuation metrics for SRPT.


What is the Short Interest ratio of SAREPTA THERAPEUTICS INC (SRPT) stock?

The outstanding short interest for SAREPTA THERAPEUTICS INC (SRPT) is 7.22% of its float. Check the ownership tab for more information on the SRPT short interest.


SRPT Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SRPT. When comparing the yearly performance of all stocks, SRPT is a bad performer in the overall market: 93.17% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SRPT Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to SRPT. SRPT has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SRPT Financial Highlights

Over the last trailing twelve months SRPT reported a non-GAAP Earnings per Share(EPS) of 2.28. The EPS increased by 137.25% compared to the year before.


Industry RankSector Rank
PM (TTM) 12.37%
ROA 5.94%
ROE 15.4%
Debt/Equity 0.74
Chartmill High Growth Momentum
EPS Q2Q%219.15%
Sales Q2Q%65.94%
EPS 1Y (TTM)137.25%
Revenue 1Y (TTM)52.98%

SRPT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to SRPT. The Buy consensus is the average rating of analysts ratings from 31 analysts.

For the next year, analysts expect an EPS growth of 214.63% and a revenue growth 63.91% for SRPT


Ownership
Inst Owners101.88%
Ins Owners4.36%
Short Float %7.22%
Short Ratio2.98
Analysts
Analysts83.23
Price Target154.99 (144.04%)
EPS Next Y214.63%
Revenue Next Year63.91%